Skip to main content

Table 1 The main baseline patients’ characteristics. Demographic, anthropometric, metabolic, and radiographic factors for all the KOA patients included in the study and stratified by knee osteoarthritis inflammatory phenotypes (KOIP). All subjects are female patients diagnosed with symptomatic primary knee osteoarthritis (KOA) with persistent joint effusion. Continuous parameters are described with their median and ranges (minimum and maximum values), while absolute frequencies and percentages are displayed for categorical variables

From: Specific-cytokine associations with outcomes in knee osteoarthritis subgroups: breaking down disease heterogeneity with phenotyping

 

All, 168 (100%)

KOIP-1, 55 (32.7%)

KOIP-2, 51 (30.4%)

KOIP-3, 27 (16.1%)

KOIP-4, 35 (20.8%)

p-value

Age at recruitment

69.1 [50.9, 83.0]

70.4 [50.9, 81.4]

68.2 [51.4, 83.0]

66.9 [54.4, 80.8]

70.4 [51.1, 80.5]

0.5195

Kellgren-Lawrence radiographic grade

Grade 1

19 (11.3%)

5 (9.1%)

4 (7.8%)

3 (11.1%)

7 (20.0%)

0.1261

Grade 2

65 (38.7%)

19 (34.5%)

25 (49.0%)

7 (25.9%)

14 (40.0%)

Grade 3

78 (46.4%)

26 (47.3%)

22 (43.1%)

16 (59.3%)

14 (40.0%)

Grade 4

6 (3.6%)

5 (9.1%)

0 (0.0%)

1 (3.7%)

0 (0.0%)

Disease evolution time (months)

48 [4, 200]

45 [4, 150]

48 [4, 200]

36 [6, 125]

60 [6, 172]

0.7291

Obesity

94 (56.0%)

51 (92.7%)

5 (9.8%)

16 (59.3%)

22 (62.9%)

< 0.0001

Physical exercise

None

61 (36.3%)

29 (52.7%)

12 (23.5%)

6 (22.2%)

14 (40.0%)

0.0123

Sporadic

51 (30.4%)

18 (32.7%)

16 (31.4%)

8 (29.6%)

9 (25.7%)

Moderate

46 (27.4%)

6 (10.9%)

18 (35.3%)

11 (40.7%)

11 (31.4%)

Vigorous

10 (6.0%)

2 (3.6%)

5 (9.8%)

2 (7.4%)

1 (2.9%)

Diabetes mellitus

18 (10.7%)

10 (18.2%)

2 (3.9%)

2 (7.4%)

4 (11.4%)

0.1101

Arterial hypertension

92 (54.8%)

37 (67.3%)

18 (35.3%)

16 (59.3%)

21 (60.0%)

0.008

Dyslipidaemia

68 (40.5%)

26 (47.3%)

16 (31.4%)

9 (33.3%)

17 (48.6%)

0.2321

ATP III metabolic syndrome

61 (36.3%)

33 (60.0%)

2 (3.9%)

9 (33.3%)

17 (48.6%)

< 0.0001

  1. ATP III Adult Treatment Panel III